Subsequent Events

12 Months Ended

Dec. 31, 2011

(9)	Subsequent Events

On December 29, 2011, we entered into a sales agreement (the “Sales Agreement”) with Cowen and Company, LLC to sell shares of the Company's common stock, par value $.01 per share, having aggregate sales proceeds of $39.75 million, from time to time, through an “at the market” equity offering program under which Cowen and Company, LLC will act as sales agent. During the first quarter through March 5, 2012, we sold approximately 0.5 million shares of our common stock through the program for net proceeds of approximately $2.0 million. The net proceeds were used for general corporate purposes, including, but not limited to, commercialization of our products, obtaining regulatory approvals, funding of our clinical trials, capital expenditures and working capital. We have approximately $37.7 million available under the program.

Delcath completed an evaluation of the impact of any subsequent events through the date financial statements were issued and determined there were no other subsequent events requiring disclosure in or adjustment to these financial statements.